Results 91 to 100 of about 16,507 (152)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics. [PDF]

Molecules
Liang JJ, Cao S, Hung A, El-Osta A, El-Osta A, Karagiannis TC, Young MJ.   +6 more
europepmc   +1 more source

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review. [PDF]

Cureus
George V, Pillai MH, Jacob V, Mp R, Vasant A, Adnan H.   +5 more
europepmc   +1 more source

Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Zaheen M, Ferdous F, Amarasekera AT, Petutschnigg J, Edelmann F, Tan TC.   +5 more
europepmc   +1 more source

Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists. [PDF]

Cureus
Okunlola AO, Kolawole O, Otabor E, Hassan A, Hamilton M, Alomari L, Lam J, Idowu AB.   +7 more
europepmc   +1 more source

Mineralocorticoid Receptor Antagonists and Cognitive Outcomes in Cardiovascular Disease and Beyond: A Systematic Review. [PDF]

J Pers Med
Pastena P, Campagnoli G, Rahmani AR, Kalogeropoulos AP.   +3 more
europepmc   +1 more source

Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. [PDF]

Front Pharmacol
Wang TY, Zhang L, Wang HY, Jiang FF.
europepmc   +1 more source

Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Landucci L, Faxén UL, Benson L, Dahlström U, Carrero JJ, Savarese G, Lund LH.   +6 more
europepmc   +1 more source

Erratum: Author Corrections to "The Effect of Mineralocorticoid Receptor Antagonists on Heart Failure with Nonreduced Ejection Fraction: A Systematic Review and Meta-Analysis [CJC Open. Volume 7, Issue 10, Pages 1332-1344. doi:10.1016/j.cjco.2025.05.021]". [PDF]

CJC Open
De Luca C, Bhatt H, Gupta A, Yahyavi A, Banivaheb B, Rayner D, Anderson K, Zieroth S, Virani SA, Foroutan F, Aleksova N.   +10 more
europepmc   +1 more source